While clinical data for AMT-130 remains strong, the FDA's insistence on a costly and time-consuming Phase III trial introduces significant development risk and timeline uncertainty. The strengthened balance sheet supports long-term funding, but investors should monitor the design and feasibility of the future trial, as well as safety developments in AMT-191 and AMT-162.
Price Chart
Executive Summary
uniQure reported financial results for 2025, showing a revenue decline to $16.1 million and a reduced net loss of $199.0 million, or $3.46 per share, compared to $239.6 million in 2024. The company highlighted clinical progress in its gene therapy pipeline, particularly durable data for AMT-130 in Huntington’s disease, but disclosed that the FDA rejected the use of external controls for approval and mandated a randomized Phase III trial. With $622.5 million in cash, uniQure is funded into 2029.
Key Financial Metrics
Key Facts
- Revenue decreased to $16.1 million in 2025 from $27.1 million in 2024, driven by lower collaboration and contract manufacturing revenue.
- Net loss narrowed to $199.0 million ($3.46/share) from $239.6 million ($4.92/share) in 2024.
- FDA rejected approval pathway for AMT-130 based on single-arm trial with external controls; required a randomized, sham-controlled Phase III study.
- AMT-130 showed statistically significant 75% slowing in disease progression at 36 months in high-dose patients.
- Cash, cash equivalents, and investments totaled $622.5 million as of December 31, 2025, up from $367.5 million in 2024.
- Cash runway now extends into the second half of 2029, supported by $404.2 million raised in public offerings in 2025.
- Development of AMT-191 paused due to dose-limiting liver toxicities; AMT-162 enrollment remains on hold after a serious adverse event.
Financial Impact
Revenue down $11 million YoY; net loss reduced by $40.6 million; cash increased by $255 million primarily from equity financing.
Risk Factors
- FDA requirement for a sham-surgery controlled trial for AMT-130 increases development cost, timeline, and ethical/enrollment challenges.
- Clinical holds and safety concerns in AMT-191 and AMT-162 could delay or derail other pipeline programs.
- Dilution risk from prior share issuances (11.8M shares + 0.5M pre-funded warrants) may weigh on shareholder sentiment despite improved cash position.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3247245 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | 8-K | $46.23 $44.47 | ▼ −3.81% | ▼ −2.85% | $23.46 (−49.25%) |
Jul 29, 2026 9w ago | 8-K | $40.07 $44.24 | ▲ +10.41% | ▲ +4.88% | $23.46 (−41.45%) |
Jul 7, 2026 12w ago | Insider Cluster | $41.41 $41.52 | ▼ −0.27% | ▲ +0.29% | $23.46 (+43.35%) |
Jul 2, 2026 13w ago | Insider Cluster | $41.81 $44.48 | ▼ −6.39% | ▼ −5.46% | $23.46 (+43.89%) |
Jul 2, 2026 13w ago | Insider Cluster | $41.81 $44.48 | ▲ +6.39% | ▲ +5.46% | $23.46 (−43.89%) |
Jul 2, 2026 13w ago | 144 | $41.81 $44.48 | ▲ +6.39% | ▲ +5.46% | $23.46 (−43.89%) |
Jun 30, 2026 13w ago | 144 | $45.17 $41.41 | ▼ −8.32% | ▼ −8.59% | $23.46 (−48.06%) |
Jun 25, 2026 14w ago | 144 | $47.51 $41.81 | ▲ +12.00% | ▲ +14.16% | $23.46 (+50.62%) |
Jun 24, 2026 14w ago | 424B5 | $49.10 $45.17 | ▼ −8.00% | ▼ −9.56% | $23.46 (−52.22%) |
Jun 24, 2026 14w ago | 144 | $49.10 $45.17 | ▼ −8.00% | ▼ −9.56% | $23.46 (−52.22%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access